Original Investigation January 25, 2022 Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 Matthew E. Oster, David K. Shay, John R. Su, et al JAMA. 2022;327(4):331-340. doi:10.1001/jama.2021.24110 Key Points Question  What is the risk of myocarditis after mRNA-based COVID-19 vaccination in the US? Findings  In this descriptive study of 1626 cases of myocarditis i...

ORIGINAL ARTICLE Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation Steffen Desch, Anne Freund, Ibrahim Akin, et al N Engl J Med 2021; 385:2544-2553DOI: 10.1056/NEJMoa2101909 Abstract BACKGROUND Myocardial infarction is a frequent cause of out-of-hospital cardiac arrest. However, the benefits of early coronary angiography and revascularization in resuscitated patients without electrocardiographic evidence of ST-segment elevatio...

COMMENT|ONLINE FIRST High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 Cynthia So-Osman, Sarah J Valk et al Lancet Published:January 27, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00112-X Many initiatives have developed passive immune therapies for COVID-19 patients, including plasma from convalescent donors. Hyperimmune immunoglobulins (hIVIG), extracted from large amounts of COVID-19 convalescent plasma (CCP), ...

Opinion Can we trust strong recommendations based on low quality evidence? Liang Yao, Gordon H Guyatt, Benjamin Djulbegovic BMJ 2021; 375 doi: https://doi.org/10.1136/bmj.n2833 (Published 25 November 2021)Cite this as: BMJ 2021;375:n2833 A necessary requirement for development of trustworthy guidelines is to respect the relation between the quality (certainty) of evidence and strength of recommendations. Strong recommendations are justified when they are based...

ARTICLES|ONLINE FIRST Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial The ITAC (INSIGHT 013) Study Group Lancet Published: January 27, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00101-5 Summary Background Passive immunotherapy using hyperimmune intravenous immunoglobulin (hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available, sp...

ARTICLES|ONLINE FIRST Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial Aurélien Mazeraud, Matthieu Jamme, Rossella Letizia Mancusi, et al Lancet Respir Med Published: November 11, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00440-9 Summary Background Acute respiratory distress syndrome (ARDS) is a major complic...

ARTICLES| VOLUME 399, ISSUE 10323, P437-446, JANUARY 29, 2022 Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study Nicole Wolter, Waasila Jassat, Sibongile Walaza, et al Lancet 2022; 399: 437-446 DOI: https://doi.org/10.1016/S0140-6736(22)00017-4 Summary Background The SARS-CoV-2 omicron variant of concern was identified in South Africa in November, 2021, and was associated with an incr...

ARTICLES|ONLINE FIRST Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study Jean-Pierre Gangneux, Eric Dannaoui, Arnaud Fekkar, et al Lancet Respir Med Published: November 26, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00442-2 Summary Background Patients with severe COVID-19 have emerged as a population at high risk of invasive fungal infections (IFIs). However, to our knowl...

ARTICLES|ONLINE FIRST Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial Zelalem Temesgen, Charles D Burger, Jason Baker, et al Lancet Respir Med Published: December 01, 2021 DOI:https://doi.org/10.1016/S2213-2600(21)00494-X Summary Background The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Gra...

ICU Management & Practice, Volume 21 - Issue 5, 2021 Mitigating the Risk of Harm During the Transition From Controlled to Assisted Mechanical Ventilation Monitoring the strength of the patient´s breathing effort, titrating the sedation, and selecting the correct mode of ventilation is vital when transitioning from controlled to assisted ventilation. Assessing The Transition From Fully Controlled to Assisted Ventilation One of the key issues with mecha...